From: Factors associated with the survival of prostate cancer patients with rectal involvement
 | n (%) or mean ± SD | Hazard ratio (95% confidence interval) | p value |
---|---|---|---|
Age | 72.04 ± 8.427 | 1.044(0.998-1.093) | 0.063 |
Grouped by age | Â | Â | Â |
<73 | 37(44.58%) | 1 | Â |
≥73 | 46(55.42%) | 1.521(0.696-3.326) | 0.293 |
Race | Â | Â | Â |
Non-Asian | 24(27.59%) | 1 | Â |
Asian | 63(72.41%) | 0.291(0.140-0.606) | 0.001 |
Clinical symptoms | Â | Â | Â |
Hydronephrosis | Â | Â | Â |
No | 70(80.4%) | 1 | Â |
Yes | 17(19.54%) | 0.904(0.389-2.104) | 0.786 |
Dysuria | Â | Â | Â |
No | 69(79.31%) | 1 | Â |
Yes | 18(20.69%) | 1.939(0.783-4.805) | 0.815 |
Dyschezia | Â | Â | Â |
No | 27(31.03%) | 1 | Â |
Yes | 60(68.97%) | 1.193(0.557-2.556) | 0.650 |
bowel obstruction | Â | Â | Â |
No | 80(91.9%) | 1 | Â |
Yes | 7(8.1%) | 0.821(0.292-2.310) | 0.709 |
Rectum bleeding | Â | Â | Â |
No | 67(77.01%) | 1 | Â |
Yes | 20(22.99%) | 2.145(1.023-4.498) | 0.043 |
The Time to development of RI | |||
Synchronous presentation | 58(66.67%) | 1 | Â |
Metachronous presentation | 29(33.33%) | 14.339(5.719-35.952) | 0.000 |
Tumor characteristics at diagnosis of rectal involvement | |||
Pathological grade of RI | Â | Â | Â |
well or moderately differentiated | 12(17.14%) | 1 | Â |
poorly differentiated | 58(82.86%) | 2.048(0.474-8.853) | 0.337 |
Histology of prostate cancer RI | Â | Â | Â |
adenocarcinoma | 81(93.10%) | 1 | Â |
Mixed type | 6(6.90%) | 0.356(0.048-2.615) | 0.310 |
CEA | Â | Â | Â |
<5Â ng/mL | 26(83.87%) | 1 | Â |
≥5 ng/mL | 5(16.13%) | 2.795(0.510-15.331) | 0.237 |
CA199 | Â | Â | Â |
<37 u/mL | 23(85.19%) | 1 | Â |
≥37 u/mL | 4(14.81%) | 2.150(0.223-20.768) | 0.508 |
PSA | 464.74 ± 1189.28 | 1.000(0.998-1.000) | 0.499 |
PSA | Â | Â | Â |
<92.41 u/mL | 28(52.83%) | 1 | Â |
≥92.41 u/mL | 25(47.17%) | 0.136(0.153-1.248) | 0.122 |
Type of rectal involvement | Â | Â | Â |
Type I | 9(13.04%) | 1 | Â |
Type II | 40(57.97%) | 0.494(0.151-1.615) | 0.244 |
Type III | 11(15.94%) | 1.163(0.311-4.346) | 0.822 |
Type IV | 9(13.04%) | 1.653(0.433-6.304) | 0.462 |
Hormonal status | Â | Â | Â |
No prior hormonal therapy | 61(70.11%) | 1 | Â |
Prior hormonal therapy | 26(29.89%) | 14.658(6.042-35.561) | 0.000 |
Tumor extent at diagnosis of RI | Â | Â | Â |
rectum-only | 24(35.82%) | 1 | Â |
Extrarectal metastases | 43(64.18%) | 2.618(0.984-6.961) | 0.054 |